MAPT and neurodegenerative disease: Importantly, by focusing solely on acetylcholinesterase activity, these compounds fail to address the multifactorial nature of Alzheimer’s and related neurodegenerative diseases, where amyloid plaque formation, tau pathology, oxidative stress, and neuroinflammation all contribute to disease progression [44].